Ieq Capital LLC Buys Shares of 41,997 Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• Ieq Capital LLC made a new investment of approximately $232,000 in Enanta Pharmaceuticals, acquiring about 41,997 shares during the 1st quarter.
• Enanta Pharmaceuticals reported ($0.85) earnings per share for the quarter, exceeding expectations of ($1.25), with revenue of $18.31 million.
• The stock has an average price target of $22.25 and is rated as a "Buy" by four research analysts, indicating positive sentiment towards its future performance.

Ieq Capital LLC bought a new stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 41,997 shares of the biotechnology company's stock, valued at approximately $232,000. Ieq Capital LLC owned approximately 0.20% of Enanta Pharmaceuticals as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. US Bancorp DE acquired a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at $36,000. Tower Research Capital LLC TRC boosted its stake in shares of Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 2,274 shares in the last quarter. GAMMA Investing LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at $40,000. Squarepoint Ops LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $66,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $75,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock traded down $0.38 during trading hours on Friday, reaching $8.28. 223,754 shares of the company's stock traded hands, compared to its average volume of 152,052. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $13.37. The firm has a market capitalization of $177.03 million, a price-to-earnings ratio of -1.92 and a beta of 0.84. The firm's 50 day moving average is $7.86 and its 200-day moving average is $6.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. The company had revenue of $18.31 million for the quarter, compared to the consensus estimate of $16.21 million. Analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a research report on Monday, July 28th. They set a "buy" rating and a $20.00 price target on the stock. JMP Securities upped their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 12th. Finally, Westpark Capital assumed coverage on shares of Enanta Pharmaceuticals in a research report on Tuesday, September 2nd. They set a "buy" rating and a $24.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.